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Objectives. This prospective study was performed to analyze the
frequency and clinical characteristics of idiopathic dilated cardio-
myopathy (DCM).
Background. Despite several previous reports on families with
DCM, most cases are still believed to be sporadic, and specific
clinical findings of the familial form are not well defined.
Methods. In 445 consecutive patients with angiographically
proven DCM, we obtained detailed family histories to construct
pedigrees and examined 970 first- and second-degree family
members.
Results. Familial DCM was confirmed in 48 (10.8%) of the 445
index patients and was suspected in 108 (24.2%). The 156 patients
with suspected or confirmed familial disease were younger at the
time of diagnosis (p < 0.03) and more often revealed electrocar-
diographic changes (p 5 0.0003) than patients with nonfamilial
disease. Among the families of the 48 index patients with con-
firmed familial disease, five phenotypes of familial DCM could be
identified: 1) DCM with muscular dystrophy; 2) juvenile DCM
with a rapid progressive course in male relatives without muscu-
lar dystrophy; 3) DCM with segmental hypokinesia of the left
ventricle; 4) DCM with conduction defects; and 5) DCM with
sensorineural hearing loss.
Conclusions. Up to 35% of patients with DCM may have an
inherited disorder. Distinct clinical phenotypes can be observed in
some families, suggesting a common molecular cause of the
disease.
(J Am Coll Cardiol 1998;31:186–94)
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The etiology of idiopathic dilated cardiomyopathy (DCM) is
largely unknown (1). Accurate diagnosis of DCM in affected
subjects and analysis of the molecular causes are limited
because of the low sensitivity and specificity of diagnostic signs
and symptoms and the low specificity of noninvasive diagnostic
procedures. Therefore, most cases of DCM are still classified
as sporadic, and segregation analysis is not part of routine
clinical evaluation, despite several previous reports on familial
aggregation of DCM (2–13). However, in recently published
prospective studies on patients with DCM and their family
members, (14,15) 20–25% of index patients were classified as
having an inherited disease. Because the diagnosis of familial
DCM depends on both the completeness of the pedigree
analysis and the diagnostic criteria used, familial DCM may be
even more prevalent. A careful analysis of the family members
of patients with DCM may reveal a typical phenotype pattern
within a single family. Based on these phenotypic characteris-
tics of familial DCM, molecular causes of the disease were
identified, such as mitochondrial DNA mutations in maternally
transmitted cardiomyopathy (16–18) and mutations of the
dystrophin gene in X-linked DCM (19–21). In families char-
acterized by DCM and conduction defects, linkage analysis
revealed linkage on chromosomes 1p1q1 (22,23), 3p22–p25
(24) and 9 (25). Recently, Bowles et al. (26) found a linkage of
the disease with chromosome 10 in a family with the phenotype
DCM and mitral valve prolapse.
Therefore, the aim of the present study was to perform
segregation analysis in a large cohort of patients with invasively
proven DCM to determine the frequency of familial disease. In
case of evidence of familial disease, as many members of each
family as possible were examined to describe the clinical
characteristics of familial DCM. It was thought that by these
analyses the role of genetic factors in DCM could be assessed,
and more efficient approaches could be delineated to investi-
gate the molecular causes of DCM and to risk stratify the
affected family members.
Methods
Index patients. In this prospective study we analyzed 481
consecutive patients with DCM. DCM was confirmed by left
ventricular and coronary angiography performed at the Uni-
versity Hospital of Heidelberg between January 1, 1988 and
March 6, 1994. The diagnosis of DCM was based on the World
Health Organization criteria (1). Only patients with an angio-
graphic left ventricular ejection fraction ,50% were included.
Exclusion criteria were coronary artery disease (.50% diam-
eter stenosis of at least one major coronary artery), valvular
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heart more than trivial, congenital heart disease, long-standing
hypertension with diastolic blood pressure .95 mm Hg, active
myocarditis, type I insulin-dependent diabetes mellitus, hypo-
thyroidism and hyperthyroidism, amyloid disease, thalassemia,
sarcoidosis, hypertrophic cardiomyopathy with dilative course,
alcohol ingestion .100 g/day and a history of exposure to
cardiotoxic drugs. Forty-six patients with type II diabetes
mellitus, two with ulcerative colitis and one with peripartum
cardiomyopathy were included because these conditions may
be a genetic predisposition for DCM. The study protocol was
approved by the ethics committee on human research of the
University of Heidelberg, and all participants gave written
informed consent before entering the study.
Segregation analysis. A detailed family history was ob-
tained by interviewing 445 of the 481 index patients. The
remaining 36 patients either refused (n 5 5), were unable to
report (n 5 7), were lost to follow-up (n 5 22) or had a
doubtful parentage (n 5 2). The names, ages, causes of death,
cardiac symptoms and known cardiac diseases of the family
members of three to four generations were listed in the
pedigrees. All living relatives of patients with suspected famil-
ial DCM were invited for a clinical examination, and their
private and hospital physicians were asked for medical reports.
Clinical evaluation consisted of a careful patient and family
history, physical examination, a 12-lead electrocardiogram
(ECG), an echocardiogram and routine blood chemistry. Index
patients and their relatives with suspected DCM also under-
went chest radiography, exercise stress testing, 24-h Holter
monitoring and left heart catheterization.
Blood samples were taken from all index patients and
examined relatives and were analyzed as part of routine clinical
workup. The analyses were used for the exclusion criteria for
DCM listed above. A 12-lead ECG was recorded for all
patients and family members investigated.
Echocardiography. Two-dimensional echocardiography
was performed using conventional equipment (Toshiba SSH
160A, Aloka SSD 870, 2.5-MHz transducers). Left and right
ventricular and atrial diameters were measured using standard
methods (27). Left ventricular function was classified as nor-
mal, mildly, moderately and severely impaired. Valvular func-
tion was evaluated using color and continuous wave Doppler
techniques. The echocardiograms were read in blinded manner
by a single experienced observer (H.K.).
Cardiac catheterization and endomyocardial biopsy. Left
and right heart catheterizations, including coronary angiogra-
phy, were performed using the standard transfemoral ap-
proach. Left ventricular ejection fraction was measured by the
area–length method in the 30° right anterior oblique projec-
tion. Segmental wall motion abnormalities were classified as
hypokinesia, akinesia or dyskinesia in one or two standard
segments of the left ventricle (anterobasal, anterolateral, api-
cal, diaphragmal, posterobasal, septal and posterolateral) ob-
tained in the 30° right and left anterior oblique projections. Six
endomyocardial biopsy specimens were taken from the free
wall or interventricular septum of the left ventricle.
Histopathologic studies. Right and left heart endomyocar-
dial biopsy specimens (n 5 134), samples from explanted
hearts (n 5 29) and heart tissue obtained at necropsy (n 5 8)
were examined using light and electron microscopy. All histo-
logic analysis were read in blinded manner by two investiga-
tors. Concordance between readers was .95%. Criteria for
diagnosis of DCM were inhomogenous hypertrophy of cardi-
omyocytes, diffuse interstitial myocardial fibrosis, absence of
fiber disarray and absence of inflammatory cells. The histologic
findings were compatible with DCM in all patients in the study
group.
Audiologic examination. In two families with suspected
familial sensorineural hearing loss a detailed audiologic exam-
ination was performed, including otoscopy, pure tone audiom-
etry, stapedial reflex measurement and tympanometry. In case
of abnormal findings, acoustic brain stem reflexes and transi-
tory evoked otoacoustic emissions were measured, and com-
puter tomographic scans of the temporal bone were per-
formed.
Follow-up examination. All index patients with familial
disease and their relatives were requested to return for reeval-
uation within 6 to 12 months. At the follow-up visit, physical
examination, blood chemistry testing, ECG recording and
echocardiographic study were performed by the same physi-
cian (E.G.).
Definition of familial disease. Familial DCM was defined
as confirmed when, in addition to the index patient, at least one
first- or second-degree relative had DCM documented either
by left heart catheterization or by autopsy. Familial DCM was
defined as suspected when at least one additional first-degree
family member had either died suddenly or died of chronic
heart failure before the age of 65 years, or when impaired left
ventricular function was documented by echocardiography.
Statistical methods. Results are presented as mean
value 6 SD. Differences in numeric clinical variables of index
patients with familial and nonfamilial disease were assessed
using the unpaired Mann-Whitney rank sum test; differences
between proportions were analyzed using the Pearson chi-
square or Fisher exact test, as appropriate; p , 0.05 was
considered statistically significant.
Results
Frequency of familial DCM (Fig. 1). A detailed family
history could be obtained in 445 (92.5%) of the 481 index
patients with a definite DCM and complete pedigrees were
constructed. This analysis revealed evidence of familial disease
Abbreviations and Acronyms
ASD 5 atrial septal defect
AV 5 atrioventricular
CK 5 creatine kinase
DCM 5 idiopathic dilated cardiomyopathy
ECG 5 electrocardiogram, electrocardiographic
WPW5 Wolff-Parkinson-White
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in 156 patients. In this group, 739 first- and second-degree
family members were examined clinically. Of the 289 patients
without evidence for familial disease, 231 first- and second-
degree family members were investigated. Based on hard data
(invasive investigations or autopsy), DCM was found in the
families of 48 index patients (10.8%) (confirmed familial
DCM). In the families of these 48 patients, 65 additional
members had definite DCM. Remarkably, 38 of the 65 DCM
cases were newly identified during the family screening pro-
cess. In 108 (24.2%) of the 445 index patients, familial DCM
was eventually present because of a history of unexplained
heart failure (n 5 23) or sudden cardiac death (n 5 75), or
both, or unexplained depressed left ventricular function on
echocardiography (n 5 10) (suspected familial DCM). In the
remaining 289 (65%) of the 445 index patients, family history
did not reveal evidence for additional family members with
DCM (nonfamilial DCM). On examination, concomitant car-
diac abnormalities, such as unspecific ECG changes (n 5 69),
mitral valve prolapse (n 5 22), Wolff-Parkinson-White (WPW)
syndrome (n 5 12), atrial septal aneurysm (n 5 4), atrial septal
defect (n 5 2), ventricular septal defect (n 5 1) and pulmonary
stenosis (n 5 1) were found in 120 of the 970 family members
with normal left and right ventricular function. In five index
patients with familial and four with sporadic disease, DCM was
associated with WPW syndrome. Seven of the 481 index
patients had identical twins; in 2 index patients, both twins
were affected.
Clinical characteristics of index patients with familial or
sporadic DCM. Index patients with suspected or confirmed
familial DCM were examined clinically and investigated by left
heart characterization at a significantly younger age than the
index patients with a negative family history (Table 1). Patients
with familial DCM more often revealed ST segment and T
wave changes than did index patients with a negative family
history. The distribution of the remaining variables tested,
including functional status at a mean follow-up of 4.01 6 3.58
Figure 1. Patient groups.
Table 1. Clinical Characteristics of Index Patients With Familial or
Nonfamilial Dilated Cardiomyopathy
Familial DCM
(n 5 156)
Nonfamilial
DCM
(n 5 289)
p
Value
Baseline characteristics
Age at 1st exam (yr) 49.79 6 12.84 53.57 6 11.91 0.007*
Age at cardiac cath (yr) 51.21 6 12.72 54.34 6 11.98 0.027*
Duration of disease (yr) 4.16 6 4.36 3.93 6 3.09 0.884*
Functional status
NYHA I/II 75 (48.08%) 139 (48.10%) 0.997†
NYHA III/IV 81 (51.92%) 150 (51.90%) 0.997†
Course
Stable 90/102 (88.24%) 149/176 (89.22%) 0.803†
Deteriorated 12/102 (11.76%) 18/176 (10.78%) 0.803†
Transplantation 20 (12.82%) 36 (12.46%) 0.921†
Death 37 (23.72%) 84 (29.07%) 0.272†
ECG findings
AV block 23 (14.74%) 34 (11.76%) 0.370†
LBBB 52 (33.33%) 111 (38.41%) 0.289†
RBBB 7 (4.49%) 16 (5.54%) 0.633†
AF 52 (33.33%) 81 (28.03%) 0.243†
Lown class 4b 59/111 (53.15%) 89/178 (50.00%) 0.602†
HR .100 beats/min 58 (37.18%) 89 (30.80%) 0.172†
ST-T wave abnorm 83 (53.21%) 103 (35.64%) 0.0003†
Echo findings
LA diameter (mm) 46.39 6 7.51 46.43 6 7.79 0.957*
LVED diameter (mm) 64.26 6 8.99 65.36 6 10.04 0.330*
LVES diameter (mm) 51.39 6 12.48 52.10 6 12.32 0.648*
FS (%) 20.72 6 8.86 19.75 6 7.47 0.425*
X-ray findings
Cardiothoracic ratio 0.55 6 0.06 0.55 6 0.07 0.741*
Pulmonary congestion 58/134 (43.28%) 85/244 (35.25%) 0.105†
*Mann-Whitney rank-sum test. †Chi-square test. Data presented are mean
value (6SD) or number (%) of patients. abnorm 5 abnormalities; AF 5 atrial
fibrillation; AV 5 atrioventricular; cath 5 catheterization; DCM 5 dilated
cardiomyopathy; ECG 5 electrocardiographic; Echo 5 echocardiographic;
exam 5 examination; FS 5 fractional shortening; HR 5 heart rate; LA 5 left
atrial; LBBB 5 left bundle branch block; LVED 5 left ventricular end-diastolic;
LVES 5 left ventricular end-systolic; NYHA 5 New York Heart Association;
RBBB 5 right bundle branch block.
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years, was not significantly different in patients with and
without familial DCM.
Clinical phenotypes in index patients with confirmed fa-
milial DCM (Table 2). In 28 of 48 families with confirmed
familial DCM, at least two members with definite DCM and
two with suspected DCM in at least two generations were
identified. Five distinct phenotypic presentations varying in
mode of inheritance, clinical symptoms, disease progression
and prognosis could be identified in 19 of these 28 families
(Tables 3 and 4). Nine families were not classified as a distinct
phenotype because of their heterogenous clinical findings.
Phenotype A: X-linked recessive DCM with muscular dystro-
phy. Two families were found in which six juvenile patients
with a mean age of 28.4 years showed a rapidly progressive
course of DCM, with elevated serum activity of total creatine
kinase (CK). During a mean follow-up period of 4 years, two
male patients have died, and one has undergone transplanta-
tion (Table 3). All patients revealed impaired right and left
ventricular function. Depressed left ventricular function was
also observed in two female patients 46 and 68 years old. The
pedigree of family A is shown in Figure 2 as an example of this
type of DCM. (Note: Only the core families are shown in
Table 2. Phenotypes of Familial Dilated Cardiomyopathy and Their Clinical Definitions
Phenotype A
(DCM with
muscular
dystrophy)
Phenotype B
(juvenile DCM with
rapid progressive course
in males)
Phenotype C
(DCM with
heterogenous
clinical course)
Phenotype D
(DCM with early
conduction system
disease)
Phenotype E
(DCM with segmental
hypokinesia)
Phenotype F
(families with DCM
and sensorineural
hearing loss)
Clinical Characteristics
Cardiac symptoms
predominant
Elevated CK
serum activity
Early onset of symptoms
and rapid progression
in males
Normal CK serum
activity
Relatives with no signs of
DCM reveal other
pathologic cardiac
findings: (e.g., WPW,
ASD)
Clinical course highly
variable
AV block
AF
Regionally impaired
LV function
Stable course
Severely impaired LV
and RV function
Bilateral pantonal
hearing loss
Mode of Inheritance
X-chromosomal X-chromosomal? Autosomal dominant Autosomal dominant Autosomal dominant Maternal or
autosomal
dominant
Molecular Genetic Definition
Mutation of
dystrophin gene
Unknown Unknown Chromosomes 1, 3, 9 Unknown Mitochondrial DNA
deletion?
ASD 5 atrial septal defect; CK 5 creatine kinase; LV 5 left ventricular; RV 5 right ventricular; WPW 5 Wolff-Parkinson-White syndrome; other abbreviations
as in Table 1.
Table 3. Phenotypes of 28 of 48 Families With Confirmed Familial Dilated Cardiomyopathy and Their Clinical Characteristics
Phenotype A
(DCM with
muscular dystrophy)
Phenotype B
(juvenile DCM with
rapid progressive
course in males)
Phenotype C
(DCM with
segmental
hypokinesia)
Phenotype D
(DCM with
early conduction
system disease)
Phenotype E
(DCM with
sensorineural
hearing loss)
Not Classified
(DCM with
heterogenous
clinical course)
No. of families 2 5 5 6 1 9
No. of family members examined 26 89 65 76 27 151
Members with suspected DCM 0/26 10/89 13/65 18/76 4/27 24/151
Members with confirmed DCM 8/26 14/89 14/65 20/76 3/27 23/151
Age at diagnosis (yr)*
Male 28.4 6 13.6 23.6 6 5.8 39.5 6 22.4 46.6 6 13.0 31 52.3 6 13.3
Female 52.7 6 15.0 60.3 6 2.9 43.5 6 6.9 46.0 6 12.0 49 57.0 6 10.1
Functional status at diagnosis
NYHA I/II 5/8 5/14 9/14 6/20 1/3 6/23
NYHA III/IV 3/8 8/14 5/14 9/20 2/3 9/23
Functional status at 1-yr follow-up
Unchanged 5/8 5/14 9/14 3/20 2/3 9/23
Deteriorated 0/8 2/14 2/14 5/20 0/3 2/23
Transplantation 1/8 6/14 0/14 2/20 0/3 2/23
Death 2/8 1/14 3/14 10/20 1/3 10/23
*Mean value 6 SD. Abbreviations as in Table 1.
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Figures 2 to 7.) In this family, molecular genetic analysis
revealed a new point mutation in the rod region exon 29 of the
dystrophin gene (21).
Phenotype B: juvenile DCM with rapid progressive course in
male patients. This phenotype was observed in five families in
which 14 members were classified as confirmed DCM and 10 as
having suspected DCM. Similar to group A, the clinical course
of DCM was rapidly progressive in all nine male patients
(mean age at diagnosis 23.6 years). During a mean follow-up
period of 5.2 years, two patients deteriorated, 6 underwent
heart transplantation, and one died. Mean age at diagnosis
(p , 0.0001) and functional status after a 6- to 12-month
follow-up period (p , 0.0004) in the male patients were
significantly different from that of patients with DCM in
groups C to F. In the five female patients with impaired left
ventricular function, mean age at diagnosis was 60.3 years, and
clinical status was unchanged at follow-up. In all affected male
and female patients, total serum CK activity was normal.
Dystrophinopathy was ruled out by histopathologic and mo-
lecular genetic analyses in one family of this group (data not
shown; methods described elsewhere [21]). The pedigree of
family B is shown in Figure 3.
Phenotype C: familial DCM with segmental hypokinesia. In
five families comprising 14 patients, DCM was characterized
by an autosomal dominant trait and by regional wall motion
abnormalities. This finding, which was documented in all 14
patients by left ventricular angiography and echocardiography
and was not seen in the other patients with DCM (p , 0.0001),
was also documented in 9 of the 289 index patients with
nonfamilial disease but in none of their examined relatives.
Figure 2. Family A: familial DCM with muscular dystrophy. The
21-year old index patient (IV-16) had DCM with right and left heart
failure. He had no neurologic findings but had exercise-induced
cramps in the lower limbs and revealed elevated total serum CK
activity. His cardiac function deteriorated rapidly, requiring emergency
heart transplantation. His 11-year old brother (IV-14) and 25-year old
nephew (IV-12) showed elevation of serum CK activity and ECG
changes. The female carriers of the disease (II-16, III-21, III-24)
revealed ECG abnormalities. Symbols 5 symbol key for Figures 2 to 7.
Figure 3. Family B: Juvenile DCM with rapid progressive course in
male relatives. In this family, three brothers (two from their mother’s
first and one from her second marriage) underwent heart transplan-
tation at 23, 26 and 36 years of age, respectively (III-8, III-4, III-3). The
carrier of the disease is the 56-year old asymptomatic mother of the
index patient (II-3), who showed impaired left ventricular function.
The father of the index patient (II-2) and all 42 members of his family
(not shown) had normal cardiac findings. Symbols as in Figure 2.
Table 4. Electrocardiographic and Echocardiographic Findings in 28 of 48 Families With Confirmed Familial Dilated Cardiomyopathy
Phenotype A
(DCM with
muscular dystrophy)
Phenotype B
(juvenile DCM with
rapid progressive
course in males)
Phenotype C
(DCM with
segmental
hypokinesia)
Phenotype D
(DCM with
early conduction
system disease)
Phenotype E
(DCM with
sensorineural
hearing loss)
Not Classified
(DCM with
heterogenous
clinical course)
ECG findings
AF 0/8 1/14 3/14 14/20 2/3 8/23
PVBs, Lown class 4b 2/8 0/14 2/14 6/20 1/3 7/23
AV block I, II or III 0/8 0/14 1/14 7/20 2/3 8/23
LBBB 1/8 0/14 1/14 2/20 0/3 5/23
ST-T wave abnorm 1/8 8/14 5/14 3/20 0/3 7/23
Echo findings
LVED diameter (mm) 57.6 6 20.6 67.8 6 10 62.1 6 15.0 55.2 6 9.4 59.0 6 9.5 67.3 6 9.2
Segmental dysfunction 0/8 0/14 14/14 0/20 0/3 0/23
Data presented are mean value 6SD or number of patients. PVBs 5 premature ventricular beats; other abbreviations as in Table 1.
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Due to the presence of regionally impaired left ventricular
function, 10 of the 14 patients with familial DCM were first
diagnosed as having had a myocardial infarction, but subse-
quent coronary angiographic findings were normal in all 14. In
9 of the 14 affected patients, the mild clinical symptoms
remained stable over a follow-up period of 4 to 10 years. The
pedigree of family C is shown in Figure 4. Autosomal dominant
inheritance was likely in this family and in the four other
families of this group.
Phenotype D: familial DCM with early conduction defects.
This group comprises six families. Of the 76 members exam-
ined, 20 developed DCM. In all 20 patients, either atrial
fibrillation (n 5 14) or atrioventricular (AV) block (n 5 7) was
documented before impaired left ventricular function could be
documented. The incidence of atrial fibrillation and AV block
was significantly higher (p 5 0.002) in this group than in groups
A to C and F. The pattern of inheritance was compatible with
an autosomal dominant trait (Fig. 5).
Phenotype E: familial DCM with sensorineural hearing loss.
In one family DCM was associated with bilateral sensorineural
hearing loss in 3 of 27 family members examined. The mode of
inheritance in this family is most likely autosomal dominant or
maternal. The pedigree of family E is shown in Figure 6.
Nonclassified families. In a further nine families, DCM was
characterized by a highly variable clinical course in the affected
23 members within each family and by cardiac abnormalities,
such as aneurysm of the interatrial septum, congenital heart
disease and conduction abnormalities, in 18 other family
members with normal left ventricular function. The mean age
at diagnosis was 52.3 years in male and 57.0 years in female
relatives. After a follow-up period of 6 to 12 months, nine
patients remained unchanged, whereas two deteriorated, two
underwent transplantation, and 10 died. The mode of inheri-
tance in these families were autosomal dominant. Figure 7
shows the pedigree of family NC as an example.
Discussion
Frequency of familial DCM. In this prospective study of
451 consecutive index patients with invasively documented
DCM, 10.8% had to be classified as having confirmed familial
disease, that is, DCM definitely existed in at least 1 additional
first-degree relative of the index patient. If more liberal
diagnostic criteria of familial DCM are accepted (e.g., a history
of unexplained heart failure or depressed left ventricular
function in a first-degree relative), an additional 24.2% of all
DCM cases can be classified as familial. Thus, ;35.0% of all
patients with DCM may have a genetic disease. The frequency
of familial aggregation of DCM documented in our study is
slightly higher than that previously reported by others (14,15).
The importance of familial screening can be stressed by the
fact that 38 new DCM cases were detected by this method in
our study.
Figure 4. Family C: DCM with segmental hypokinesia. All affected
living members revealed segmental hypokinesia, ECG changes and a
stable course at 5-year follow-up. Child IV-6 died of proven DCM at
13 years of age. Child IV-16 died of heart failure awaiting transplan-
tation. This child had a small atrial septal defect, mild pulmonary
stenosis and a persistent open ductus ateriosus Botalli. Symbols as in
Figure 2.
Figure 5. Family D: DCM with early conduction system disease. Thirty
of 64 family members were examined. Five of the eight siblings in
generation III died of confirmed DCM at 34, 35, 41, 42 and 54 years of
age, respectively (III-6, III-16, III-8, III-4, III-10). The carrier of the
disease was probably the mother (II-7), who died of DCM at 64 years
old. All affected members developed atrial fibrillation at a young age,
and five of the six patients with DCM required permanent cardiac
pacing because of AV blocks. Symbols as in Figure 2.
Figure 6. Family E: DCM with sensorineural hearing loss. DCM and
bilateral pantonal sensorineural hearing loss were documented in
three siblings (III-7, III-11, III-12). The mother (II-7) and grand-
mother (I-4) of the index patient died of sudden death at 65 and 68
years of age. All members of the family without cardiac disease showed
normal results on audiograms. Symbols as in Figure 2.
191JACC Vol. 31, No. 1 GRU¨NIG ET AL.
January 1998:186–94 FREQUENCY AND PHENOTYPES OF FAMILIAL DCM
Clinical characteristics of patients with familial DCM.
When index patients with familial DCM were compared with
those with sporadic DCM, ECG ST segment and T wave
changes were more frequently observed in those with familial
disease. Similar differences were not reported in previous
investigations (13–15). However, such ECG changes are not
specific for familial DCM and are not useful for clinical
classification. Furthermore, patients with familial disease were
also identified at an earlier age (51.21 6 12.72 years) than
patients with sporadic disease (54.34 6 11.98, p , 0.03).
Because of the prospective nature of our study, the earlier
identification of patients with familial DCM cannot be ex-
plained by a more extensive family screening but may instead
be related to earlier manifestation of inherited than sporadic
DCM.
Phenotypes of familial DCM. In families with hypertrophic
cardiomyopathy, distinct mutations have been related to dif-
ferences in symptoms and progression of the disease (28,29).
Phenotyping of patients with familial DCM may therefore
facilitate genetic screening and improve their diagnostic clas-
sification and risk stratification. The assumption underlying
this proposal is that the phenotypic heterogeneity observed
reflects underlying genetic heterogeneity of familial DCM.
In our study, although five different clinical phenotypes
could be identified, this does not preclude the existence of
additional phenotypes. The phenotype A (e.g., X-linked DCM
with elevated total serum CK activity) has been described
before (30), and mutations of the dystrophin gene have been
reported as causing this type of DCM (19,20). In our study,
this type of DCM was observed in 2 of 48 families with
confirmed familial disease. In family A (represented in Fig.
3), a novel point mutation in exon 29 of the dystrophin gene
was detected (21). Thus, it is likely that DCM with this
phenotype is caused by mutations of dystrophin or
dystrophin-associated proteins.
Many clinical characteristics of patients with X-linked dys-
trophin disease, such as rapid progressive deterioration of
ventricular function in male patients and late onset of a slowly
progressive disease in female patients, were observed in five
families. However, the affected members of these families did
not reveal elevated serum CK activity. Furthermore, linkage
analysis and histologic examinations of muscle biopsy speci-
mens of affected members were performed in one of these
families. These investigations did not reveal evidence of dys-
trophinopathy. Therefore, the patients with this type of DCM
were allocated to a separate group (group B).
Familial DCM may also manifest as a segmental disease of
the left ventricular myocardium (phenotype C). Segmental
hypokinesia was described earlier in patients with sporadic
disease (31,32); however, familial aggregation of this type of
DCM has not yet been reported. Because congenital heart
disease coexisted in one of the affected family members,
defects in the genes regulating cardiac development may be
involved.
The five families of phenotype D are characterized by an
autosomal dominant inheritance and the association of DCM
with AV block or atrial fibrillation, or both, early in the disease
process. This phenotype resembles that of families described
previously in which linkage of DCM with polymorphic markers
located on the centromeric region of chromosome 1 (22,23),
chromosome 3p (24) and chromosome 9 (25) has been re-
ported.
Finally, DCM associated with sensorineuronal hearing loss
(phenotype E) has, to our knowledge, not been reported
before. Because maternal inheritance is most likely in this
family, this phenotype might be caused by mutations of
mitochondrial DNA, which has been reported previously in
patients with DCM and neurologic symptoms (18,33). Other
candidate genes that might be responsible for DCM of pheno-
type E may include Shaker 1 and USH1b genes encoding
nonsarcomeric myosins. Mutations in these genes have re-
cently been identified as causing deafness (34) or severe
bilateral hearing loss (35). The Jervell and Lange-Nielson
Figure 7. Family NC (not classified): familial DCM with heterogenous
clinical course. Of 93 family members shown, 74 are still alive, and 70
were examined. In the first and second generations, five members died
of heart failure at 55 to 64 years old. In the third and fourth
generations, DCM was confirmed by left heart catheterization or
autopsy in four members 33 to 54 years old. The clinical course of the
affected members was highly variable. Eleven family members with no
sign of DCM showed other pathologic ECG or echocardiographic
abnormalities: atrial septal aneurysm (n 5 2), mitral valve prolapse
(n 5 3), aortic regurgitation (n 5 1), WPW syndrome (n 5 1) and ST
segment and T wave changes (n 5 4). Two members (III-11, IV-12) of
one branch of the family had asymmetric hypertrophy of the interven-
tricular septum of 17 and 15 mm, respectively. Symbols as in Figure 2.
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syndrome (36) was ruled out in this family by normal QT
intervals in all family members examined. There was no
evidence of Kearns-Sayre syndrome in this family.
The largest proportion of patients with familial DCM were
characterized by heterogeneous clinical findings within the
same families and were therefore not classified as having a
distinct phenotype. In these families, autosomal dominant
inheritance and cardiac abnormalities, such as WPW syn-
drome, aneurysms of the interatrial septum and ECG changes,
were observed in family members with otherwise normal
cardiac findings. These cardiac abnormalities may represent
coincidental findings or may be causually related to the familial
disease. In several reports of families with DCM, a high
prevalence of WPW syndrome (4,37,38), mitral valve prolapse
(26,39) and ST segment and T wave changes have been
reported (13,14). Although a common molecular defect may
not exist in this group, a single mutation with high variable
penetrance and expression may explain the variability of this
phenotype.
Study limitations. Although the present investigation ex-
amined a large number of family members (970) of 445
consecutive patients with definite DCM, they represent only
part of all living family members listed in the pedigrees.
However, clinical examination was focused on the families with
a history of familial disease (739 members of 156 families),
thus reducing the likelihood of missing familial disease. By
contrast, examination of 231 family members of 289 index
patients without incidence for familial disease did not reveal
any evidence of further instances of DCM. Thus, although this
study may underestimate the true prevalence of familial DCM,
the thorough segregation analysis and the clinical examinations
of 970 family members should reduce the significance of this
possible error. Because most of the patients were referred to
our institute, a random minor referral bias may have occurred
and cannot be excluded.
Clinical implications. The results of our study indicate that
DCM may be a genetic disorder in one-third of all cases.
Consequently, pedigree analyses should be performed in all
patients with DCM. If familial DCM is suspected, all first-
degree relatives of the index patients should be examined.
Using this strategy, 38 new patients with DCM and 120 with
cardiac abnormalities were detected in the families of our 445
index patients. In sufficiently large families with aggregation of
DCM, it may be possible to identify common clinical pheno-
types. These common phenotypes of DCM may facilitate
screening for genetic defects and may help in risk stratification.
In particular, young male patients with suspected X-linked
DCM (phenotype A and B) have rapidly progressive disease
and should therefore be followed up closely.
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